Buying its own future output: the company is spending now to own more of the value it already helps create
The model's full reasoning — Q3 2021 call → NOWe need to determine if management describes the company currently moving itself further up or down its own value chain, taking ownership or direct control of a step that someone else used to perform, and that this move is already being executed and changing what the company earns or can do. Let's analyze the transcript. The company is Akebia Therapeutics, with product vadadustat for anemia due to CKD. They have a partner Otsuka for Japan and Europe, and Vifor for distribution to Fresenius dialysis providers. They have Auryxia as a commercial product. Key points: They are preparing for launch of vadadustat. They have a distribution relationship with Vifor Pharma to access Fresenius Medical Care and certain other dialysis providers. They have their own nephrology focused sales force to engage with DaVita and others. They are building supply chain, have two API and two drug product suppliers. They have a commercial team of 140 people, 110 field-based. The question: Does management describe that the company is CURRENTLY MOVING ITSELF FURTHER UP OR DOWN ITS OWN VALUE CHAIN — taking ownership or direct control of a step in the chain that someone else used to perform, own, or capture the margin on — and does management convey that this move is ALREADY BEING EXECUTED and is already changing what the company earns or can do, rather than being planned or contemplated? We need to see if they are internalizing something they previously outsourced. For example, are they taking over distribution, manufacturing, sales, etc.? From the transcript: They have a distribution relationship with Vifor for Fresenius. They have their own sales force for DaVita. They are building supply chain. They have two API and two drug product suppliers. They are preparing for launch. They have a commercial team already in place for Auryxia. Is there any mention of taking over a step that was previously done by someone else? For instance, did they previously rely on a partner for sales and now they are doing it themselves? They have always had their own sales force for Auryxia. They are leveraging that for vadadustat. They are not taking over from someone else; they are adding a product to their existing sales force. They have a partnership with Otsuka for Europe and Japan. They are not taking that over. They have a distribution agreement with Vifor for Fresenius.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| GIII | G-III Apparel Group, Ltd. | Q4 2024 | 2024-03-14 | C |
| KOPN | Kopin Corporation | Q4 2023 | 2024-03-14 | C+ |
| PFE | Pfizer Inc. | Q4 2023 | 2024-01-30 | F |
| BZUN | Baozun Inc. | Q2 2023 | 2023-08-28 | D |
| KMDA | Kamada Ltd. | Q2 2023 | 2023-08-16 | B+ |
| SOL | ReneSola Ltd | Q3 2022 | 2022-12-01 | C+ |
| TMCI | Treace Medical Concepts, Inc. | Q2 2022 | 2022-08-13 | B+ |
| HROW | Harrow Health, Inc. | Q4 2021 | 2022-03-10 | C |
| SLQT | SelectQuote, Inc. | Q2 2022 | 2022-02-07 | F |
| LC | LendingClub Corporation | Q4 2021 | 2022-01-26 | A |
| LPTH | LightPath Technologies, Inc. | Q4 2021 | 2021-09-09 | D |
| KNDI | Kandi Technologies Group, Inc. | Q2 2021 | 2021-08-09 | F |
| EHTH | eHealth, Inc. | Q2 2021 | 2021-07-29 | F |
| PRPO | Precipio, Inc. | Q3 2018 | 2018-11-19 | D |
| T | AT&T Inc. | Q3 2018 | 2018-10-24 | C+ |
| KOP | Koppers Holdings Inc. | Q2 2018 | 2018-08-12 | C+ |
| XOM | Exxon Mobil Corporation | Q2 2018 | 2018-07-27 | C |
| TOUR | Tuniu Corporation | Q4 2017 | 2018-03-14 | D |
| HSTM | HealthStream, Inc. | Q3 2017 | 2017-10-24 | C |
| FLEX | Flex Ltd. | Q1 2018 | 2017-07-28 | F |
| DAN | Dana Incorporated | Q1 2017 | 2017-05-02 | B |
| GES | Guess?, Inc. | Q1 2017 | 2016-05-25 | F |
FLEX · Q1 2018 → YESThe question is about whether Flex Ltd is currently moving itself further up or down its own value chain by taking ownership or control of a step that someone else used to perform. YES The transcript shows Flex is actively internalizing a previously external step in the shoe manufacturing value chain by taking ownership of automation, process redesign, and end-to-end production for Nike. Management describes this as an ongoing, real-time execution: “we’re vertically integrating technologies,” “rethinking all of the whole supply process we’re applying automation technologies,” “we’ve manufactured over 1 million pairs,” and “we took over the facility in September” for Bose, with the Nike factory transition “complete by October.” They explain the value capture: the company now keeps margin it previously paid away, controls quality, cost, supply, and timing previously constrained by a counterparty, and serves customers it could not reach through the old chain. While acknowledging the ramp is early (losses persist through Q2, breakeven expected by year-end), the move is already changing what Flex earns and can do, not merely planned or contemplated. This meets all three required elements.
XOM · Q2 2018 → YESThe question is about whether ExxonMobil is currently moving itself further up or down its own value chain by taking ownership or control of a step that someone else used to perform. YES The transcript shows ExxonMobil actively internalizing logistics and supply-chain steps that previously required external partners or intermediaries. Neil Chapman explicitly states they “will get engaged in the connectivity between the Permian and our Gulf Coast refining and chemical assets,” with equity participation in logistics, the Wink terminal acquisition (closed late 2017), 11 active completion crews, and a signed letter of intent for a 1 million bpd long-haul crude pipeline. These moves are already producing results: Gulf Coast refineries are “already processing our production levels and more, capturing the benefits of disadvantaged feed cost.
KMDA · Q2 2023 → YESThe question is about whether management describes the company currently moving itself further up or down its own value chain, taking ownership of a step that someone else used to perform, and that th...YES The transcript shows management describing the 2021 acquisition of the Beaumont plasma collection center as the company's entry into U.S. plasma collection, with the explicit goal of becoming a "fully integrated specialty plasma product company." They state they are "successfully expanding" capacity at the first center (already acquired and operational) and plan to open the second in Houston in early 2024. This is presented as an active, ongoing move to internalize plasma collection that previously depended on external suppliers.